< Previous         Next >  
Multi-omics profiling: the way toward precision medicine in metabolic diseases
Cheng Hu1,2 , Weiping Jia1,*
1Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
2Institute for Metabolic Disease, Fengxian Central Hospital, The Third School of Clinical Medicine, Southern Medical University, Shanghai 201499, China
*Correspondence to:Weiping Jia ,
J Mol Cell Biol, Volume 13, Issue 8, August 2021, Pages 576-593
Keyword: type 2 diabetes mellitus, non-alcoholic fatty liver disease, metabolic syndrome, biomarkers, multi-omics profiling, precision medicine

Metabolic diseases including type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS) are alarming health burdens around the world, while therapies for these diseases are far from satisfying as their etiologies are not completely clear yet...